Pliant Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases. The company's lead candidate includes bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which has completed phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325, a phase 1-ready program for treatment of the muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Show more

Location: 331 Oyster Point Boulevard, Suite 150, South San Francisco, CA, 94080, United States | Website: https://pliantrx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

71.21M

52 Wk Range

$1.10 - $16.10

Previous Close

$1.16

Open

$1.16

Volume

1,440,178

Day Range

$1.13 - $1.26

Enterprise Value

-174.3M

Cash

305.6M

Avg Qtr Burn

-43.52M

Insider Ownership

3.04%

Institutional Own.

-

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.